Skip to main content

Cormorant Asset Management, LP

Position in NAMS — NewAmsterdam Pharma Co N.V.

CIK 1583977 BOSTON, MA

Position in NAMS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$16,945,000
-$13,464,500 QoQ
Shares Held
500,000
-47.4% QoQ
Ownership
0.418%
of shares outstanding
% of Portfolio
0.86%
of 13F equity value
Holder Rank
#41
of 198 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NAMS Over Time

Shares Held

Position Value (USD)

Derivatives in NAMS

reported options exposure · as of Mar 31, 2025
CallValue
$5,117,500
CallShares
250,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Cormorant Asset Management, LP holds $1,889,506,429 across 46 Biotechnology names. NAMS ranks #28 (0.9% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in NAMS

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $16,945,000 500,000
2026-03-31 $30,409,500 950,000
2025-12-31 $35,080,000 1,000,000
2025-09-30 $61,857,000 2,175,000
2025-06-30 $39,389,250 2,175,000
2025-03-31 $5,117,500 250,000
2025-03-31 $57,827,750 2,825,000
2024-12-31 $83,525,000 3,250,000
2024-09-30 $41,002,000 2,470,000
2024-06-30 $44,183,000 2,300,000
2024-03-31 $35,475,000 1,500,000